A phase 2a proof of concept clinical trial to evaluate ZPL-3893787 (ZPL-389) a potent, oral histamine H4, receptor antagonist for the treatment of moderate to severe atopic dermatitis (AD) in adults
Thomas Werfel(Medizinische Hochschule Hannover), W. Liu, B. Cimoszko, Arjen Nikkels(Centre Hospitalier Universitaire de Liège), Bernadetta Majorek‐Olechowska, Kristine Breuer, Petra Staubach(Johannes Gutenberg University Mainz), Aliya Asher, Gary Layton(University of Geneva), Lyndsey A. Whitlock(Ziarco (United Kingdom)), Alexander Gawlik, Bhanu Gupta, Anna Płoszczuk, Victoria Lynch(Metropolitan Arts Centre), Krzysztof Buczyłko, Athanasios Tsianakas(University Hospital Münster), R. Sarmiento, T Hofman, M. Morren, M. Yeadon, Lynn Purkins(Ziarco (United Kingdom))
Open Repository and Bibliography (University of Liège)
January 1, 2016
Cited by 15
Related Papers
The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
|Allergy|2018|1.4k
EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy
|Allergy|2014|1.4k